The therapeutic potential of targeting Oncostatin M and the interleukin-6 family in retinal diseases: A comprehensive review.

IF 1.7 4区生物学 Q3 BIOLOGY

Open Life Sciences Pub Date : 2024-12-31 eCollection Date: 2024-01-01 DOI:10.1515/biol-2022-1023

Tommaso Mori, Nareshkumar Ragavachetty Nagaraj, Pier Luigi Surico, Wenjing Zhou, Uday Pratap Singh Parmar, Fabiana D'Esposito, Caterina Gagliano, Mutali Musa, Marco Zeppieri

{"title":"The therapeutic potential of targeting Oncostatin M and the interleukin-6 family in retinal diseases: A comprehensive review.","authors":"Tommaso Mori, Nareshkumar Ragavachetty Nagaraj, Pier Luigi Surico, Wenjing Zhou, Uday Pratap Singh Parmar, Fabiana D'Esposito, Caterina Gagliano, Mutali Musa, Marco Zeppieri","doi":"10.1515/biol-2022-1023","DOIUrl":null,"url":null,"abstract":"<p><p>Retinal diseases, which can lead to significant vision loss, are complex conditions involving various cellular and molecular mechanisms. The interleukin-6 (IL-6) family, particularly Oncostatin M (OSM), has garnered attention for their roles in retinal inflammation, angiogenesis, and neuroprotection. This comprehensive review explores the dual nature of OSM and other IL-6 family members in retinal pathophysiology, highlighting their contribution to both degenerative and regenerative processes. The review also examines current research on OSM's interaction with key signaling pathways and discusses the potential of OSM and the IL-6 family as potential therapeutic targets. Understanding these mechanisms could lead to innovative treatments that modulate OSM activity, offering new avenues for managing retinal diseases and contributing to the development of more effective interventions.</p>","PeriodicalId":19605,"journal":{"name":"Open Life Sciences","volume":"19 1","pages":"20221023"},"PeriodicalIF":1.7000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699559/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Life Sciences","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1515/biol-2022-1023","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Retinal diseases, which can lead to significant vision loss, are complex conditions involving various cellular and molecular mechanisms. The interleukin-6 (IL-6) family, particularly Oncostatin M (OSM), has garnered attention for their roles in retinal inflammation, angiogenesis, and neuroprotection. This comprehensive review explores the dual nature of OSM and other IL-6 family members in retinal pathophysiology, highlighting their contribution to both degenerative and regenerative processes. The review also examines current research on OSM's interaction with key signaling pathways and discusses the potential of OSM and the IL-6 family as potential therapeutic targets. Understanding these mechanisms could lead to innovative treatments that modulate OSM activity, offering new avenues for managing retinal diseases and contributing to the development of more effective interventions.

查看原文本刊更多论文

靶向Oncostatin M和白细胞介素-6家族治疗视网膜疾病的潜力：综述

视网膜疾病是一种复杂的疾病，涉及多种细胞和分子机制，可导致严重的视力丧失。白细胞介素-6 （IL-6）家族，特别是肿瘤抑制素M (OSM)，因其在视网膜炎症、血管生成和神经保护中的作用而引起了人们的关注。这篇综合综述探讨了OSM和其他IL-6家族成员在视网膜病理生理中的双重性质，强调了它们对退行性和再生过程的贡献。本文还回顾了目前关于OSM与关键信号通路相互作用的研究，并讨论了OSM和IL-6家族作为潜在治疗靶点的潜力。了解这些机制可能会导致调节OSM活动的创新治疗方法，为管理视网膜疾病提供新的途径，并有助于开发更有效的干预措施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Open Life Sciences BIOLOGY-

CiteScore

2.50

自引率

4.50%

发文量

131

审稿时长

43 weeks

期刊介绍： Open Life Sciences (previously Central European Journal of Biology) is a fast growing peer-reviewed journal, devoted to scholarly research in all areas of life sciences, such as molecular biology, plant science, biotechnology, cell biology, biochemistry, biophysics, microbiology and virology, ecology, differentiation and development, genetics and many others. Open Life Sciences assures top quality of published data through critical peer review and editorial involvement throughout the whole publication process. Thanks to the Open Access model of publishing, it also offers unrestricted access to published articles for all users.